At A Glance
Pharma marketers can support more informed health journeys when patient and HCP messaging is relevant, privacy-forward, and optimized against meaningful outcomes. In this Ask the Expert conversation, Experian and DeepIntent discuss how health marketers can coordinate education, CTV, activation workflows, and measurement without entering private clinical decisions.Privacy-forward pharma media supports more informed healthcare journeys
Effective pharma marketing depends on reaching patients, caregivers, and healthcare professionals (HCPs) with useful information in appropriate, privacy-forward ways. The goal is to make relevant education easier to find, support more informed conversations, and help brands understand how media contributes across the health journey.
In this Ask the Expert session, Natalie Mancuso, SVP, Data Partnerships at DeepIntent, joins Sheila Wirick, who leads the health team at Experian, to discuss how to craft patient and HCP campaigns, privacy-safe activation workflows, connected TV (CTV), and measurement approaches built for pharma.
Why should your media plan start with understanding the patient and provider
The patient-and-provider journey should inform your media plan, as treatment decisions in pharma are increasingly informed, personal, and patient-driven. With more health information available than ever, patients are playing a more active role in understanding their options and participating in treatment conversations. As other industries become more customer-centric, pharma media planning needs to become more patient-centric.
“We’ve got patients who are more informed, more involved in their treatment decisions than ever. The accessibility of data and information and the ways we can consume it with just AI alone is so vast that if we’re not arming people with the right information in real time, we’re missing the boat.”
DeepIntentNatalie Mancuso, SVP, Data Partnerships
This means media should be aligned to where a patient or provider is in the decision journey and what they need at that moment. Early on, media may play an educational role by building awareness of a condition, symptom, or treatment category. Later, it may help support more specific questions, treatment consideration, access, affordability, or adherence.
The patient-provider conversation remains the key boundary. That exchange should stay private and clinically led. Media can play a valuable role before and after those moments by offering information that helps patients and providers feel more informed.
How can brands connect patient and HCP messaging responsibly?
It’s critical for agencies and brands to deliver relevant messaging to inform each stakeholder’s needs throughout the treatment journey, especially ahead of key clinical milestones. To execute this, brands must exercise privacy-forward activation, keeping patient and HCP identity, activation, and measurement paths separate, while using a common workflow layer to support the same brand goal.
Experian helps pharma marketers do this by acting as an independent, privacy-forward identity, data, and workflow layer. We bring together high-fidelity matching, governed onboarding, and non-clinical consumer context, so patient and HCP engagement can be activated more accurately across channels and connected to reporting.
The distinction is not only where each audience is reached. HCPs may be engaged in both professional and personal environments, but their needs are different from patients’. For example, an HCP may receive messaging about co-pay savings for eligible patients, while a patient may receive information about patient support programs. These are different messages for different audiences, but they ladder up to the same goal: informing both parties in a privacy-forward, relevant way.
Hear from Natalie Mancuso in our 2026 State of advertising report
In our 2026 State of advertising report, Natalie shares why identity serves as the connective infrastructure that links planning, activation, and measurement across connected TV (CTV), programmatic, commerce media, and walled garden environments.
What does privacy-forward activation look like in pharma?
Pharma brands often start with fragmented patient and HCP signals. Privacy-forward activation turns those inputs into usable audiences by first confirming that the data can be used, then translating identity in controlled environments that protect personally identifiable information through tokenization or other methodologies.
For DTC, that means building and matching audiences without relying on inferred health conditions from browsing behavior. For HCPs, it means connecting professional identity to verified sources in a way that supports activation and measurement. In a category shaped by HIPAA, state privacy laws, internal review, and consumer sensitivity, building privacy in from sourcing through activation is what makes responsible health media possible.
How can CTV play a more useful role in pharma?
CTV can play a more useful role in healthcare when it’s connected to a larger, privacy-forward plan and not treated as just an awareness channel.
DeepIntent connects CTV and digital exposure data using identity signals, such as National Provider Identifiers (NPIs), hashed email addresses, IP addresses, device IDs, and household signals, where permitted and reviewed. That identity layer helps support sequencing and suppression across streaming, endemic, mobile, and digital settings.
In practice, CTV can introduce targeted education or broad brand awareness, and later touchpoints can provide sequential information in the right channels. Instead of repeating the same message, brands can make pivots based on engagement and context.
“For us, it starts with identity and not panels. When we’re resolving CTV and digital exposures to the same person, we’re leveraging signals so that every touchpoint across streaming, endemic, and mobile is recognized as the same individual, not model lookalikes.”
DeepIntentNatalie Mancuso, SVP, Data Partnerships
For pharma, campaign performance should not be measured by reach alone. A stronger approach looks at whether sequenced engagement contributes to meaningful downstream signals, including:
- Prescription activity
- Provider engagement
- Referral patterns
- Patient compliance
- Adherence signals, where measurement is permitted
Why should messaging and reporting change in pharma?
Pharma campaigns are journeys with changing information needs. Reporting should guide the campaign optimization.
“If I’m launching into a market with a new class of drug, I’m asking what education needs to be put into the market – from both an HCP and a consumer standpoint – to build awareness?”
DeepIntentNatalie Mancuso, SVP, Data Partnerships
Clicks and website visits still have a place, but they can’t tell the full pharma story. DeepIntent processes data in real time, giving brands an up-to-date read on how media connects to campaign engagement. Campaign signals can help teams optimize audience logic, creative, channel mix, or sequencing during a live campaign.
Explore how privacy-safe pharma activation can make an impact
Experian brings marketing data and identity expertise for health marketing and DeepIntent adds pharma-specific activation experience. Together, we help brands connect patient and HCP strategies responsibly, with privacy built in from the start.
Watch the full video with our experts to hear Sheila Wirick and Natalie Mancuso discuss patient and HCP messaging, CTV, privacy-safe activation, and outcome measurement for pharma brands.
About our experts
Natalie Mancuso
SVP, Data Partnerships, DeepIntent
Natalie Mancuso is SVP, Data Partnerships at DeepIntent and a leader in health-focused AdTech and DSP strategy. With over 20 years of experience growing billion-dollar healthcare brands, she turns complex data into scalable, performance-driven solutions that keep marketers ahead of industry change.
Sheila Wirick
Director of Health Sales, Experian
Sheila Wirick is the Director of Health Sales at Experian with more than 20 years of experience in data and analytics. As Director of Health Sales at Experian Marketing Services, she collaborates with healthcare, pharmaceutical, and nonprofit organizations to apply data and insights that enhance customer retention, brand awareness, and acquisition. She is committed to helping organizations use data to deliver measurable results and meaningful impact.
FAQs
A pharma audience is activation-ready when patient or HCP inputs can be translated into usable audiences with the right accuracy, controls, interoperability, and destination readiness. For patient engagement, that may include privacy-safe cohort construction, caregiver logic, non-clinical enrichment and appropriate exclusion rules. For HCP engagement, it may include governed identity inputs such as NPI, specialty, practice location, professional address and other verified attributes where appropriate.
Pharma brands can sequence messages responsibly by giving each channel a clear role and using audience logic to maintain continuity. CTV and out-of-home can support awareness, social can reinforce the message, search can capture active research and point-of-care or rep-triggered channels can support decision moments. The workflow should preserve separation between patient and HCP identity strategies.
Pharma marketers should measure whether media connects to outcomes such as audience quality, prescription activity, qualified HCP engagement, verified delivery, referral patterns, therapy starts or adherence signals where permitted. These outcomes often depend on partner-enabled workflows, clean rooms, and aggregated outputs rather than direct end-to-end tracking.
Experian acts as an independent privacy-first identity, data, and workflow layer for pharma marketers. We help brands bring together identity, high-fidelity matching, governed onboarding, non-clinical consumer context, and partner interoperability so patient and HCP engagement can be activated more accurately across channels and connected more cleanly to partner-enabled measurement.
Latest posts
Tapad, now a part of Experian, announces forward progress through The Trade Desk integration
Featured storiesWith campaigns applied to seven major holding companies, Tapad continues to see healthy adoption with The Trade Desk clients NEW YORK, NY – August 23, 2017 – Tapad, now a part of Experian, the leader in cross-device marketing technology, today announced its ongoing momentum with The Trade Desk, Inc. (Nasdaq: TTD), a global technology platform for buyers of advertising. Tapad is providing cross-device segments from the groundbreaking Tapad Device GraphTM through The Trade Desk’s platform. Since 2015, Tapad has seen steady growth in the use of its cross-device data across The Trade Desk platform. This forward progress continues, as 1H2017 saw important milestones for Tapad. Seven major private and independent holding companies now apply Tapad’s data to their campaigns, in addition to more than 1,500 unique brands. Tapad’s proprietary Device GraphTM connects billions of devices, providing unified and insightful data for brands, agencies, and marketers across the globe. Several of these clients, representing varying industries from financial, to auto, CPG and retail, apply Tapad’s data across a number of key tactics and strategies, including: first party CRM extension, third party audience extension, cross-device retargeting, cross-device frequency management, and more. Clients in these verticals continue to rely on Tapad’s cross-device data, as Tapad saw the amount of usage by financial and retail clients grow by four times over the past year, and double for automotive and CPG clients. “We are pleased to offer our clients access to Tapad’s device graph”, said David Danziger, VP of Data Partnerships, The Trade Desk. “Their cross-device identification capabilities have been a powerful addition to our omnichannel platform.” Contact us today
Tapad, a part of Experian, partners with Sojern to simplify the complex travel consumer journey
Featured storiesTapad Device Graph™ and Sojern’s mobile offering unify travel intent signals; achieve amplification rate of more than 600 percent NEW YORK, June 15, 2017 — Tapad, a part of Experian, the leader in cross-device marketing technology, is partnering with Sojern, travel’s direct demand engine, to provide marketers with an even stronger understanding of travelers as they research and shop across multiple devices. Combined with its 350 million global traveler profiles and billions of predictive purchase intent signals, Sojern utilizes the Tapad Device Graph™ to resolve the complex travel consumer journey, target travelers more precisely, and derive more actionable insights for its travel clientele. According to Sojern’s research, travelers visit hundreds of websites preceding their trip purchase, with some consumers reaching upwards of 450 touchpoints prior to booking. Sojern’s partnership with Tapad will help unify these touchpoints across devices, enabling travel brands to more effectively nurture and engage potential buyers during the purchase process, regardless of which device they use. “Sojern’s been focused on travel for over a decade, helping brands activate predictive purchase signals and leverage our traveler profiles into effective performance marketing campaigns,” said Mat Harris, Sojern’s VP of Product, Enterprise Solutions. “The cross-device insights we gain from the Tapad Device Graph provide a valuable tool for our customers to reach travelers across devices in real-time and at scale, on the right device.” Prior to selecting Tapad as its cross-device partner, Sojern surveyed several probabilistic and deterministic cross-device vendors and performed an extensive global test. The test was an examination of scale, match rate and several other factors, which enabled Sojern to learn as much as possible about each vendor. After examining the final test results, Sojern selected Tapad based on its excellent test performance, tried-and-true experience in the market and complimentary business model. To date, Sojern has already seen an amplification rate of more than 600 percent as a result of the integration, meaning that the Tapad Device Graph is connecting an average of six or more device and browser IDs for every one existing Sojern ID. “Not only is Sojern a compatible partner for our singular Device Graph capabilities, but they are also an incredible data partner to help expand our work in the travel industry,” said Pierre Martensson, SVP and GM of Tapad’s global data division. “Working with the team at Sojern allows us to solve a true challenge within the travel industry today: creating a unified view of customers so travel brands can better understand and access their key audiences at every point along their path to purchase.” Contact us today
Tapad, now a part of Experian, partners with Resonate to enhance audience analytics for mobile app brands
Featured storiesLeading data insights and cross-device-powered services bridge mobile insights with connectivity to drive real-time consumer intelligence NEW YORK, May 17, 2017 /PRNewswire/ — Tapad, now a part of Experian, the leader in cross-device marketing technology, has partnered with Resonate, a leading provider of real-time consumer intelligence and activation SaaS solutions. Through this partnership, Resonate will leverage the Tapad Device Graph™ to capture a deeper understanding of its mobile app audiences and provide brands with a more direct connection to their intended consumers. The integration of Resonate and Tapad’s technologies equips mobile app brands with insights into their consumers’ values, beliefs, motivations and purchase drivers. As a result, mobile app brands will better understand how to tailor messaging, drive advertising engagement, increase lift in performance across mobile consumers and ultimately boost revenue and returns. Utilizing the advanced data that the Tapad Device Graph™ provides, Resonate will create an Identity Service that connects mobile IDs to Resonate IDs for reporting insights both in-platform and out. To date, Tapad and Resonate have already driven incremental device connections for nearly 60 percent of customer profiles with an amplification rate of more than 120 percent, resulting in more than 400 million net new IDs within Resonate’s user base. “After testing multiple partners over the course of 12 months, it was clear that Tapad was the partner for us, given their ability to provide cross-device connectivity for more than one billion unique IDs against our consumer base,” said Joel Pulliam, SVP and chief product officer at Resonate. “In addition, Resonate customers have an inherent trust in Tapad’s mix of probabilistic and deterministic mobile connectivity data to provide a unified understanding of their mobile audiences.” “Partnering with Resonate will not only provide its brands with a more in-depth and actionable understanding of its consumers, but it will also allow our clients to connect with mobile consumers on a deeper level,” said Pierre Martensson, SVP and GM of Tapad’s global data division. “Resonate is not just answering the question of ‘how’ consumers are making purchases, but also tackling the more difficult question of ‘why’ they make certain buying decisions to best inform mobile brands about their audiences.” Contact us today